OBJECTIVE: Nicotinic acid (NA) treatment has been associated with benefits in atherosclerosis that are usually attributed to effects on plasma lipoproteins. The NA receptor GPR109A is expressed in monocytes and macrophages, suggesting a possible additional role for NA in modulating function of these immune cells. We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo. METHODS AND RESULTS: In human monocytes activated by Toll-like receptor (TLR)-4 agonist lipopolysaccharide, NA reduced secretion of proinflammatory mediators: TNF-α (by 49.2±4.5%); interleukin-6 (by 56.2±2.8%), and monocyte chemoattractant protein-1 (by 43.2±3.1%) (P<0.01). In TLR2 agonist, heat-killed Listeria monocytogenes-activated human monocytes, NA reduced secretion of TNF-α (by 48.6±7.1%), interleukin-6 (by 60.9±1.6%), and monocyte chemoattractant protein-1 (by 59.3±5.3%) (P<0.01; n=7). Knockdown of GPR109A by siRNA resulted in a loss of this anti-inflammatory effect in THP-1 monocytes. However, inhibition of prostaglandin D2 receptor by MK0524 or COX2 by NS398 did not alter the anti-inflammatory effects of NA observed in activated human monocytes. Preincubation of THP-1 monocytes with NA 0.1 mmol/L reduced phosphorylated IKKβ by 42±2% (P<0.001) IKB-α by 54±14% (P<0.01). Accumulation of nuclear p65 NF-κB in response to lipopolysaccharide treatment was also profoundly inhibited, by 89±1.3% (n=4; P<0.01). NA potently inhibited monocyte adhesion to activated HUVEC, and VCAM, mediated by the integrin, very late antigen 4. Monocyte chemotaxis was also significantly reduced (by 45.7±1.2%; P<0.001). CONCLUSION: NA displays a range of effects that are lipoprotein-independent and potentially antiatherogenic. These effects are mediated by GPR109A and are independent of prostaglandin pathways. They suggest a rationale for treatment with NA that is not dependent on levels of plasma cholesterol and possible applications beyond the treatment of dyslipidemia.
OBJECTIVE: Nicotinic acid (NA) treatment has been associated with benefits in atherosclerosis that are usually attributed to effects on plasma lipoproteins. The NA receptor GPR109A is expressed in monocytes and macrophages, suggesting a possible additional role for NA in modulating function of these immune cells. We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo. METHODS AND RESULTS: In human monocytes activated by Toll-like receptor (TLR)-4 agonist lipopolysaccharide, NA reduced secretion of proinflammatory mediators: TNF-α (by 49.2±4.5%); interleukin-6 (by 56.2±2.8%), and monocyte chemoattractant protein-1 (by 43.2±3.1%) (P<0.01). In TLR2 agonist, heat-killed Listeria monocytogenes-activated human monocytes, NA reduced secretion of TNF-α (by 48.6±7.1%), interleukin-6 (by 60.9±1.6%), and monocyte chemoattractant protein-1 (by 59.3±5.3%) (P<0.01; n=7). Knockdown of GPR109A by siRNA resulted in a loss of this anti-inflammatory effect in THP-1 monocytes. However, inhibition of prostaglandin D2 receptor by MK0524 or COX2 by NS398 did not alter the anti-inflammatory effects of NA observed in activated human monocytes. Preincubation of THP-1 monocytes with NA 0.1 mmol/L reduced phosphorylated IKKβ by 42±2% (P<0.001) IKB-α by 54±14% (P<0.01). Accumulation of nuclear p65 NF-κB in response to lipopolysaccharide treatment was also profoundly inhibited, by 89±1.3% (n=4; P<0.01). NA potently inhibited monocyte adhesion to activated HUVEC, and VCAM, mediated by the integrin, very late antigen 4. Monocyte chemotaxis was also significantly reduced (by 45.7±1.2%; P<0.001). CONCLUSION: NA displays a range of effects that are lipoprotein-independent and potentially antiatherogenic. These effects are mediated by GPR109A and are independent of prostaglandin pathways. They suggest a rationale for treatment with NA that is not dependent on levels of plasma cholesterol and possible applications beyond the treatment of dyslipidemia.
Authors: Dominique Maciejewski-Lenoir; Jeremy G Richman; Yaron Hakak; Ibragim Gaidarov; Dominic P Behan; Daniel T Connolly Journal: J Invest Dermatol Date: 2006-09-28 Impact factor: 8.551
Authors: Darbie Maccubbin; Michael J Koren; Michael Davidson; Dov Gavish; Richard C Pasternak; Geraldine Macdonell; Madhuja Mallick; Christine McCrary Sisk; John F Paolini; Yale Mitchel Journal: Am J Cardiol Date: 2009-07-01 Impact factor: 2.778
Authors: Christina A Bursill; Robin P Choudhury; Ziad Ali; David R Greaves; Keith M Channon Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Robert W Walters; Arun K Shukla; Jeffrey J Kovacs; Jonathan D Violin; Scott M DeWire; Christopher M Lam; J Ruthie Chen; Michael J Muehlbauer; Erin J Whalen; Robert J Lefkowitz Journal: J Clin Invest Date: 2009-04-06 Impact factor: 14.808
Authors: D M Capuzzi; J R Guyton; J M Morgan; A C Goldberg; R A Kreisberg; O A Brusco; J Brody Journal: Am J Cardiol Date: 1998-12-17 Impact factor: 2.778
Authors: Sony Tuteja; Lu Wang; Richard L Dunbar; Jinbo Chen; Stephanie DerOhannessian; Santica M Marcovina; Marshall Elam; Ellis Lader; Daniel J Rader Journal: Pharmacogenet Genomics Date: 2017-08 Impact factor: 2.089
Authors: John R Guyton; April E Slee; Todd Anderson; Jerome L Fleg; Ronald B Goldberg; Moti L Kashyap; Santica M Marcovina; Stephen D Nash; Kevin D O'Brien; William S Weintraub; Ping Xu; Xue-Qiao Zhao; William E Boden Journal: J Am Coll Cardiol Date: 2013-07-31 Impact factor: 24.094